Dako (Glostrup, Denmark) recently announced that they will be collaborating with Amgen (CA, USA) to develop a molecular diagnostic test. The project will involve the use of Dako’s IQFISH hybridization buffer.
Dako, an Agilent Technologies (CA, USA) company, is a provider of tissue-based cancer diagnostics. The IQFISH hybridization buffer enables pathology laboratories to run DNA-based hybridization assays rapidly, reducing diagnostic test turnaround times from 17 to 3.5 hours. The manufacturers claim that in addition to its speed, the buffer results in distinct and higher fluorescent signal intensity compared with traditional FISH assays.
It is hoped that the molecular diagnostic test will make cancer diagnosis more rapid and accurate, allowing the most effective treatment for patients to be determined. In addition to improving patient care, it is also expected to reduce healthcare-related costs.
The project will add to the portfolio of existing projects in which Dako and Amgen are partners. Jacob Thaysen, Vice President and General Manager for Agilent’s Diagnostics and Genomics business, stated, “We are pleased to continue our work with Amgen, particularly within the molecular arena.”